Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mixed dyslipidemia~Exclusion Criteria:~* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.~* Patients who are taking certain medications or unstable dose of specific medications.~* Women who are pregnant or plan on becoming pregnant or women who are lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): ABT-335 + 10 mg rosuvastatin
- B (Type: ACTIVE_COMPARATOR): ABT-335 + 20 mg rosuvastatin
- C (Type: PLACEBO_COMPARATOR): ABT-335 monotherapy
- D (Type: PLACEBO_COMPARATOR): 10 mg rosuvastatin monotherapy
- E (Type: PLACEBO_COMPARATOR): 20 mg rosuvastatin monotherapy
- F (Type: PLACEBO_COMPARATOR): 40 mg rosuvastatin monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).